Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects.

Even if this news can be disappointing, the HD Community will keep positive and hope the remaining trials and tests can bring some good news.

Kategorijos: Naujienos

0 Komentarai

Parašykite komentarą

Avataro pakaitinis laikiklis

El. pašto adresas nebus skelbiamas. Būtini laukeliai pažymėti *

lt_LTLithuanian